Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study

Ebina, Kosuke; Hirano, Toru; Maeda, Yuichi; Yamamoto, Wataru; Hashimoto, Motomu; Murata, Koichi; Onishi, Akira; Jinno, Sadao; Hara, Ryota; Son, Yonsu; Amuro, Hideki; Takeuchi, Tohru; Yoshikawa, Ayaka; Katayama, Masaki; Yamamoto, Keiichi; Okita, Yasutaka; Hirao, Makoto; Etani, Yuki; Kumanogoh, Atsushi; Okada, Seiji; Nakata, Ken

doi:https://doi.org/10.1038/s41598-021-04075-0

Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study

Ebina, Kosuke; Hirano, Toru; Maeda, Yuichi et al.

Scientific Reports, 2022, 12(1), 134

Number of Access:2,897（2025-07-24 09:23 Counts）

Identifier to cite or link to this item: https://hdl.handle.net/11094/93206

Link to primary information

File	Format	Terms of use	Size	Views	Date.Available	Description	information
SciRep_12_1	pdf	None	992 KB	92	2023.11.28

Creative Commons : Attribution

Item Information

Output File Export EndNote Basic Export Mendeley

Title	Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study
Creator	NRID 1000070612076 1000070612076 researchmap permalink k-ebina k-ebina Scopus Author ID 8415453300 8415453300 ORCID 0000-0002-2426-1024 0000-0002-2426-1024 CreatorName Ebina, Kosuke
	NRID 1000010437402 1000010437402 Scopus Author ID 55456655500 55456655500 CreatorName Hirano, Toru
	NRID 1000010815658 1000010815658 Scopus Author ID 56655338200 56655338200 CreatorName Maeda, Yuichi
	CreatorName Yamamoto, Wataru
	NRID 1000060512845 1000060512845 CreatorName Hashimoto, Motomu
	NRID 1000060806793 1000060806793 CreatorName Murata, Koichi
	NRID 1000060634269 1000060634269 CreatorName Onishi, Akira
	CreatorName Jinno, Sadao
	NRID 1000010597107 1000010597107 CreatorName Hara, Ryota
	CreatorName Son, Yonsu
	CreatorName Amuro, Hideki
	NRID 1000010330078 1000010330078 CreatorName Takeuchi, Tohru
	NRID 1000020850069 1000020850069 CreatorName Yoshikawa, Ayaka
	CreatorName Katayama, Masaki
	NRID 1000070416387 1000070416387 CreatorName Yamamoto, Keiichi
	CreatorName Okita, Yasutaka
	NRID 1000010527708 1000010527708 Scopus Author ID 8883255100 8883255100 CreatorName Hirao, Makoto
	NRID 1000060898930 1000060898930 ORCID 0000-0001-5741-5969 0000-0001-5741-5969 researchmap permalink Yetani0302 Yetani0302 CreatorName Etani, Yuki
	NRID 1000010294125 1000010294125 researchmap permalink read0051725 read0051725 Scopus Author ID 6602726311 6602726311 ORCID 0000-0003-4749-7117 0000-0003-4749-7117 CreatorName Kumanogoh, Atsushi
	NRID 1000030448435 1000030448435 ORCID 0000-0002-5107-8209 0000-0002-5107-8209 researchmap permalink okadaseiji okadaseiji Scopus Author ID 35079139100 35079139100 CreatorName Okada, Seiji
	NRID 1000000283747 1000000283747 researchmap permalink ken-nakata ken-nakata Scopus Author ID 7402151308 7402151308 CreatorName Nakata, Ken
Description	Ebina K., Hirano T., Maeda Y., et al. Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study. Scientific Reports 12, 134 (2022); https://doi.org/10.1038/s41598-021-04075-0.
Abstract	This multi-center, retrospective study aimed to clarify the factors affecting drug retention of the Janus kinase inhibitors (JAKi) including baricitinib (BAR) and tofacitinib (TOF) in patients with RA. Patients were as follows; females, 80.6%; age, 60.5 years; DAS28-ESR, 4.3; treated with either BAR (n = 166) or TOF (n = 185); bDMARDs- or JAKi-switched cases (76.6%). The reasons for drug discontinuation were classified into four major categories. The drug retention was evaluated at 24 months using the Kaplan–Meier method and multivariate Cox proportional hazards modelling adjusted by confounders. Discontinuation rates for the corresponding reasons were as follows; ineffectiveness (22.3%), toxic adverse events (13.3%), non-toxic reasons (7.2%) and remission (0.0%). Prior history of anti-interleukin-6 receptor antibody (aIL-6R) ineffectiveness significantly increased the risk of treatment discontinuation due to ineffectiveness (p = 0.020). Aging (≥ 75 years) (p = 0.028), usage of PSL ≥ 5 mg/day (p = 0.017) and female sex (p = 0.041) significantly increased the risk of treatment discontinuation due to toxic adverse events. Factors not associated with treatment discontinuation were: number of prior bDMARDs or JAKi, concomitant MTX usage, difference of JAKi, and prior use of TNF inhibitor, CTLA4-Ig or other JAKi.
Publisher	Nature Research
Source Title	Scientific Reports
Volume (Issue)	12(1)
Page	134
Date of Issued	2022-01-07
Language	English
Handle URL	https://hdl.handle.net/11094/93206
eISSN	20452322
Relation.isIdenticalTo	DOI (Publisher Version) https://doi.org/10.1038/s41598-021-04075-0
Access Rights	open access
CopyRight	This article is licensed under a Creative Commons Attribution 4.0 International License.
oaire:version	Version of Record
Category	学術雑誌論文 Journal Article

Resource Type	journal article
Local Type	Journal Article
DCMI Type	Text
DCTERMS.bibliographicCitation	Scientific Reports. 2022, 12(1), p. 134
DC.title	Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study
DC.creator	Ebina, Kosuke
	Hirano, Toru
	Maeda, Yuichi
	Yamamoto, Wataru
	Hashimoto, Motomu
	Murata, Koichi
	Onishi, Akira
	Jinno, Sadao
	Hara, Ryota
	Son, Yonsu
	Amuro, Hideki
	Takeuchi, Tohru
	Yoshikawa, Ayaka
	Katayama, Masaki
	Yamamoto, Keiichi
	Okita, Yasutaka
	Hirao, Makoto
	Etani, Yuki
	Kumanogoh, Atsushi
	Okada, Seiji
	Nakata, Ken
DC.publisher	Nature Research
DC.language' scheme='DCTERMS.RFC1766	English
DC.type' scheme='DCTERMS.DCMIType	Text
DCTERMS.issued' scheme='DCTERMS.W3CDTF	2022-01-07
DC.identifier	https://doi.org/10.1038/s41598-021-04075-0
DC.description	Ebina K., Hirano T., Maeda Y., et al. Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study. Scientific Reports 12, 134 (2022); https://doi.org/10.1038/s41598-021-04075-0.
DCTERMS.abstract	This multi-center, retrospective study aimed to clarify the factors affecting drug retention of the Janus kinase inhibitors (JAKi) including baricitinib (BAR) and tofacitinib (TOF) in patients with RA. Patients were as follows; females, 80.6%; age, 60.5 years; DAS28-ESR, 4.3; treated with either BAR (n = 166) or TOF (n = 185); bDMARDs- or JAKi-switched cases (76.6%). The reasons for drug discontinuation were classified into four major categories. The drug retention was evaluated at 24 months using the Kaplan–Meier method and multivariate Cox proportional hazards modelling adjusted by confounders. Discontinuation rates for the corresponding reasons were as follows; ineffectiveness (22.3%), toxic adverse events (13.3%), non-toxic reasons (7.2%) and remission (0.0%). Prior history of anti-interleukin-6 receptor antibody (aIL-6R) ineffectiveness significantly increased the risk of treatment discontinuation due to ineffectiveness (p = 0.020). Aging (≥ 75 years) (p = 0.028), usage of PSL ≥ 5 mg/day (p = 0.017) and female sex (p = 0.041) significantly increased the risk of treatment discontinuation due to toxic adverse events. Factors not associated with treatment discontinuation were: number of prior bDMARDs or JAKi, concomitant MTX usage, difference of JAKi, and prior use of TNF inhibitor, CTLA4-Ig or other JAKi.
DC.rights	This article is licensed under a Creative Commons Attribution 4.0 International License.
DC.format	93206
citation_title	Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study
citation_author	Ebina, Kosuke
	Hirano, Toru
	Maeda, Yuichi
	Yamamoto, Wataru
	Hashimoto, Motomu
	Murata, Koichi
	Onishi, Akira
	Jinno, Sadao
	Hara, Ryota
	Son, Yonsu
	Amuro, Hideki
	Takeuchi, Tohru
	Yoshikawa, Ayaka
	Katayama, Masaki
	Yamamoto, Keiichi
	Okita, Yasutaka
	Hirao, Makoto
	Etani, Yuki
	Kumanogoh, Atsushi
	Okada, Seiji
	Nakata, Ken
citation_publisher	Nature Research
citation_language	English
citation_date	2022-01-07
citation_journal_title	Scientific Reports
citation_volume	12
citation_issue	1
citation_firstpage	134
citation_doi	https://doi.org/10.1038/s41598-021-04075-0
citation_public_url	https://hdl.handle.net/11094/93206

Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study

Link to primary information

Item Information

Show details